Pilatus Biosciences, a biopharmaceutical company developing novel metabolic checkpoint immunotherapies for cancer, today announced two intellectual property milestones for PLT012, its lead investigational anti-CD36 monoclonal antibody: receipt of a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for U.S. Patent Application No. 18/844,588 and completion of the acquisition of worldwide rights to the related patent family derived from PCT/US2023/063766.
These achievements followed the Company’s previously announced dosing of the first patient in the United States and completion of the associated development efforts. Together, these milestones give Pilatus direct ownership and control of the worldwide patent family, enabling the Company to manage its prosecution, maintain and enforce these patent rights as it advances the program in connection with potential future development, partnering and other strategic opportunities.
The patent family, titled “Anti-CD36 Antibodies and Uses Thereof,” is derived from PCT/US2023/063766 and relates to anti-CD36 antibodies including PLT012 and their therapeutic applications. The patent family describes antibodies designed to bind to human CD36 with high affinity and inhibit CD36-mediated biological functions, including fatty acid transport and associated immune-regulatory effects.
